IN SILICO ANTIMALARIAL TARGET SELECTION CONSERVED IN FOUR PLASMODIUM SPECIES by AWofisayo, Oladoja
 
 
Original Research Article 
 





The need for new antimalarials drugs and drug targets is pertinent due to the emergence of drug resistant 
strains of the parasites. Improper target selection has resulted in therapeutic failure. The genomic/post 
genomic era has made possible the deciphering of the 3D crystal structures of proteins and DNA which 
are drug targets and are deposited in the protein data bank. Novel antimalarial targets obtained from 
evolutionary conserved short sequence motifs are utilised and are essential in transcription processes in 
the parasite. The motifs TGCATGCA, GTGCAC and GTGCGTGC were curated from experimental 
work, validated and analysed via phylogenomics genomics and comparative genomics. PlasmoDB blastn 
was applied to determine their similarity in Plasmodium vivax, knowlesi, Ovale and yoeli. The complete 
genome of Plasmodium falciparum vivax, knowlesi, Ovale and yoeli was downloaded from the 
plasmoDB and their positions determined. The targets are essential, conserved in rodent and mammalian 
species via phylogenomics with percentage identity and similarity greater than 80%, have no similar 
genes in the same genome and also found to be selective in the parasites vis-à-vis the Homo sapiens via 
comparative genomics with 0% identity and similarity in the human genome. The targets reveal at the 
molecular and biochemical level, the vulnerable regions in the parasite while safe in human hence their 




Human malaria with estimated 515 million cases of is generally caused by four species of Plasmodium 
namely P. falciparum, P.vivax, P. ovale and P.malariae and are transmitted by the bite of the female 
anopheles mosquito (Snow, Guerra et al. 2005). Other mammalian Plasmodium species implicated 
include: P. knowlesi and P. yoelii. P. falciparum has the greatest toll on human health most especially in 
children under five years of age. The severity of malaria apart from the characteristic fever and anaemia 
include neurological involvement which may result in coma and subsequently to death. In the case of 
cerebral malaria, there could be damage to the hippocampus evident by impaired learning ability and 
cognitive function. The lifelong potentials of the child are therefore reduced(Boivin, Bangirana et al. 
2007). Novel drugs have been launched into the drug discovery pipelines by the Medicines for Malaria 
Venture MMV and currently MMV pathogen box (Van Voorhis, Adams et al. 2016). Notwithstanding the 
propensity of the malaria parasites to become drug resistant still poses a major problem which may 
threaten the efficacy of promising new antimalarial chemotypes such as the synthetic peroxide OZ439 
(Charman, Arbe-Barnes et al. 2011) and the spiroindolone NITD 609(Rottmann, McNamara et al. 2010) 
over time and this scenario will persist until the human-pathogenic Plasmodium species are eventually 
eradicated (Müller and Hyde 2010). 
Despite recent advances in the “omics” field Lack of sufficient understanding of biologic networks, 
incomplete understanding of the biology and dynamics of drug-target interaction, lack of efficient and 
accurate ways to determine clinical relevance and the need to integrate massive amounts of sequence and 
phenotype data from the public and private sector. Focus is placed on the generation of an inventory of 
potential targets for therapeutics based on human and pathogen genome sequence studies to replenish the 
depleted pipeline. Target identification and selection is a lengthy and complex process that is now 
expedited and improved by bioinformatic (Shaikh, Ahmed et al. 2004). 
 
 
A persistent bottleneck for target-based approaches is the identification of a suitable drug target in the 
first place(Hubbard 2011). This enzyme should be essential for survival of the parasite and sufficiently 
different from its closest counterpart in the human host to be inhibited selectively. Experimental tools to 
validate candidate drug targets are limited for the malaria parasites(Greenwood, Fidock et al. 2008). 
Several bioinformatics approaches have previously been employed to help identify or prioritise drug 
targets for Plasmodium parasites. These include methods based on automated identification of important 
steps in metabolic pathways(Plata, Hsiao et al. 2010), methods that combine chemical starting points and 
protein-based queries(Joubert, Harrison et al. 2009) , as well as the use of the TDRtargets web-resource 
(Magariños, Carmona et al. 2011) (http://www.tdrtargets.org) to prioritise drug targets through the 
combination of multiple data types relevant to drug development (Guiguemde, Shelat et al. 2010). 
A drug target must satisfy the following conditions to be selected (i) It must have conserved orthologues 
in all of the mammalian-pathogenic Plasmodium. (ii) It must have no other match in the Plasmodium 
falciparum. (iii) It must not occur or have a good match in all the human genome (chromosomes 1-23 and 
X,Y). (iv)Functions in the transcription process resulting in formation of gametocytes. The basis behind 
this principle is that conserved genes usually perform essential functions and in this case the motifs are 
essential in the regulation of gene(Doyle, Gasser et al. 2010). These criteria were applied in the selection 
of candidate drug targets that satisfy the conditions stated above. 
 
Experimental Motif detection 
Evolutionary conserved short sequence motifs in a set of promoters were curated from experimental 





The entire genome sequence of the Plasmodium falciparum was downloaded via the file transfer protocol 
ftp from the database of the National Centre for Biotechnology Information (NCBI) (ftp) site 
(ftp//.ncbi/nlm.nihgov/blast/executables/)..The download was done in the fasta format. The PlasmoDB 
http:// www.plasmodb.org/common/download( Aurrecoechea et al .,2009) and Kyoto ecyclopedia of 
genes of genes and genomes http:// www.genome.jp /kegg/ ( Aurrecoechea). The frequency of occurrence 
of the raw sequence was determined in the mammalian and rodent Plasmodium species.  
Their upstream and downstream sequences were determined after the sequences of the Plasmodium 
falciprum hence the final sequences were not less than 16base pairs long (Roche, Thomson et al. 1994). 
Blastn was applied to determine the percentage similarity and identity of the selected sequences in the 
other plasmodium species selected. 
The entire Human genome was downloaded via the file transfer protocol ftp from the database of the 
National Centre for Biotechnology Information (NCBI) ftp site. 
Homo_Sapiens.NCBI34.pep.fa.downloaded from ftpsite (ftp.// 
ftp.ensembl.org/pub/current_human/data/fasta/pep/). The download was done in the fasta format. 
Comparative genomics was applied to determine the percentage identity and similarity of the final 16 
base pair sequences in the human genome. The sequences of interest above were compared with all 
known sequences in a database to identify homologous sequences. The genomic sequences for 
Plasmodium falciparum and their functional annotations were obtained from plasma DB (version 4.1) 
software sequence similarity between P. falciparum sequence and human sequence was run on a 
standalone computer. The default parameters were selected, and the p-value was calculated to validate 
sequence similarity to a human chromosome across the 23 chromosome including the X and Y 
 
 
chromosome. The statistical significance of the similarity search in the human genome was obtained from 
the BLASTn results. 
Results 
Table 1.0 Summary of the various experimetally derived DNA Sequence Motiffs (Rs) to Target 
Sequence oligonucleotides (Ts1) via computational analysis  
 
 
 Raw Sequence in sPlasmodium 
genome 
Oligomers obtained from Motifs TS Organism in 
which motif is 
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(TS3)   
ACCAGGGTGCACAAGCA 
(TS2b)     
CATTTCGTGCACCTACAT (TS2)   





















Sequence Found in Sporozoites 
 
 
Sequence formation of Merozoite 
Sequence found in merozoites 
Dephosphorylation  






Table 2.0 Experimetally derived DNA Sequence Motiff (Rs) TGCATGCA  to Target Sequence 
16base pair oligonucleotide (Ts1) via computational analysis  
 
Query sequence Number of base pairs Frequency 
TGCATGCA 8 26 
ATGCATGCAT 10 8 
GATGCATGCATT 12 1 
TGATGCATGCATTT 14 1 
CTGATGCATGCATTTA 16 1 
 
Table 3.0 Comparative  blastn results for 16bp oligonucleotide CTGATGCATGCATTTA to 
establish identity and homology of sequence in human plasmodium species(P.falciparum, 
vivax, malariae,berghei, knowlesi and yoeli)  
 
Organism Similarity 
 Pf3D7 14v3 100% 









Table 4.0   Experimetally derived DNA Sequence Motiff (Rs2) GTGCAC to Target Sequence 
16base pair oligonucleotide ATTTCGTGCACCTACA (Ts2) via computational analysis  
 
DNA SEQUENCE (5-3), (3-5) No Of Base Pair Frequency  in 
PG 
GTGCAC 6 89 
CGTGCACC 8 1 
TCGTGCACCT 10 1 
TTCGTGCACCTA 12 1 
TTTCGTGCACCTAC 14 1 
ATTTCGTGCACCTACA 16 1 
 
Table 4.1 Comparative  blastn results for 16bp oligonucleotide ATTTCGTGCACCTACA to 
establish identity and homology of sequence in human plasmodium species(P.falciparum, 




 Pf3D7 14v3 100% 






Table 5.0   Experimetally derived DNA Sequence Motiff (Rs4) GTGCGTGC to Target Sequence 
16base pair oligonucleotide GTGTGTGCGTGCGGAT (Ts4) via computational analysis  
 
DNA sequence (5-3)(3-5)  No of Base Pair Frequency  in pG 
GTGCGTGC 8 2 
TGTGCGTGCG 10 1 
TGTGTGCGTGCGG 12 1 
TGTGTGCGTGCGGA 14 1 




Table 5.1 Comparative  blastn results for 16bp oligonucleotide GTGTGTGCGTGCGGAT to 
establish identity and homology of sequence in human plasmodium species(P.falciparum, 
vivax, malariae,berghei, knowlesi and yoeli)  
 
Organism Similarity 
 Pf3D7 14v3 0% 







Figure 1: Graph of the frequency of Occurrence of  CTGATGCATGCATTTA (TS1)against base pair 
number                      in the Plasmodium falciparum genome (pG) and Human Genome  HG1-23. 
 
Figure 2: Graph of the frequency of Occurrence of ATTTCGTGCACCTACA  (TS2) vs base pair 





Figure 3: Graph of the frequency of Occurrence of TGTGTGTGCGTGCGGA (TS4) against base pair 
number in the Plasmodium falciparum genome (pG) and Human Genome HG1-23. 
 
Discussion 
The process of searching and obtaining clearly defined targets was done via extensive literature search in 
which the motifs were finally selected, based on their various roles in the biochemical and metabolic 
processes within the Plasmodium parasites (Carlton, Adams et al. 2008). The motifs are sequences 
covered by transcription factors and are conserved between evolutionary related species( Toucan ref). The 
16 base pairs was selected as this length will represent one and a half turn of DNA so as to achieve 
specificity and selectivity in the Plasmodium parasite (Roche, Thomson et al. 1994). 
The evolutionary conserved short sequence motifs SSM TGCATGCA, GTGCAC and GTGCGTGC were 
experimentally determined and validated. Computational analyses carried out on these SSM via location 
in the downloaded Plasmodium falciparum genome gave the 16 base pair oligonucleotide sequences as 
follows CTGATGCATGCATTTA, ATTTCGTGCACCTACA and GTGTGTGCGTGCGGAT (Roche, 
Thomson et al. 1994) . The 16 base pair oligonucleotides were selected based on the criteria that a 
conserved single copy gene that lacks close matches in the same genome is most likely to be 
indispensable(Doyle, Gasser et al. 2010) . They were selected as targets based on their specific roles in 
the regulation of transcription process involved in the process of sporozoite formation as in the 
TGCATGCA motif. The second motif GTGCACACAC was essential and regulatory for the process of 
merozoite invasion into the host cell while GCACGCGTGC is involved in the regulation of 
dephosphorylation process. These motifs were found to be conserved in the four species of Plasmodium 
namely Plasmodium falciparum, P.vivax, P.knowlesi and P.yoelii yoelii. ACCTGTGCATGCAGGGAA 
(TS3) derived from the GTGCAC motif and occurs in P.vivax and identified in literature (Carlton, Adams 
 
 
et al. 2008) is also a DNA target that is explored in this study. The raw sequence motifs were found 
through computational analysis to be selective. Their frequency of occurrence in the Plasmodium 
falciparum genome was computed and then simultaneously the target sequences were obtained through 
the location in the various chromosomes.The frequency of TGCATGCA is 26 (Table 2.0) while 
GTGCAC occurs 89 times in the Plasmodium falciparum (Table 4.0) and GTGCGTGC occurs only two 
times (Table 5.0) in the Plasmodium falciparum. These frequencies of occurrence are as opposed to the 16 
base pair oligonucleotides derived from these motifs which are CTGATGCATGCATTTA, 
ATTTCGTGCACCTACA and GTGTGTGCGTGCGGAT and occur only with a frequency of one in the 
Plasmodium falciparum (Table 2.0, Table 4.0 and Table 5.0) hence fulfilling the criteria of essentiality in 
the Plasmodium falciparum and the fact that it is a single copy gene. Further bioinformatics analysis also 
allowed the frequency of occurrence in the Human genome to be calculated in chromosomes number 1-22 
and the X and Y chromosomes. The graphical representations are as presented in Figures 1, 2 and 3 
respectively for the 16 base pair oligonucleotides CTGATGCATGCATTTA (TS1), 
ATTTCGTGCACCTACA(TS2), and GTGTGTGCGTGCGGAT (TS4). The plot of the Frequency of 
occurrence of the raw motifs against the base pair numbers revealed in the case of TS1 and TS2 a clear 
distinction in the occurrence of the Plasmodium falciparum pG as distinct from the human chromosomes 
HG 1-22 and the X and Y chromosomes. These oligonucleotides are therefore selective as drug targets in 
the Plasmodium species in which they are conserved and drugs developed against them will not be toxic 
in the human.The formation of sporozoites via the sequence TS1 CTGATGCATGCATTTA. Formation 
of merozoites, however, involves ACCTGTGCATGCAGGGAA (TS2) and ACCAGGGTGCACAAGCA 
(TS3). CATTTCGTGCACCTACAT (TS4) regulates the dephosphosrylation process in the plasmodium 
parasite. CATTTCGTGCACCTACAT (TS4) The sequences were located in their respective 
chromosomes in the genome and the 16 base pair were determined via a program to obtain sequences in 
the 5’-3’position from the motif as well as the 3’-5’ position from the motif (Tables 1-3). The blastn 
revealed a similarity and identity of not less than 80% in the other species CTGATGCATGCATTTA has 
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